Acute Multiple Sclerosis Relapse

1. Clinical Overview

Summary

An acute multiple sclerosis (MS) relapse, also termed exacerbation or attack, represents a clinical manifestation of new or recurrent inflammatory demyelinating activity in the central nervous system (CNS) occurring in patients with relapsing-remitting multiple sclerosis. [1,3] By definition, a relapse consists of patient-reported symptoms or objectively observed neurological signs typical of an acute inflammatory demyelinating event in the CNS, lasting at least 24 hours, occurring in the absence of fever or infection, and separated from the onset of a previous relapse by at least 30 days. [1,3]

The pathophysiology centers on T-cell and B-cell mediated immune attack against myelin antigens, with inflammatory infiltrates causing demyelination, axonal injury, and blood-brain barrier disruption. [3,6] This acute inflammatory activity manifests clinically based on anatomical localization—optic neuritis (unilateral vision loss with pain on eye movement), partial transverse myelitis (sensory level, weakness, bladder dysfunction), brainstem syndromes (internuclear ophthalmoplegia, diplopia), or hemispheric presentations (hemiparesis, hemisensory loss). [3,5]

Critical to clinical management is differentiating true relapses from pseudo-relapses—transient symptom worsening triggered by infection, hyperthermia (Uhthoff phenomenon), or metabolic stress without new inflammatory activity. [11] Infections, particularly urinary tract infections, are identified in 30-40% of suspected relapses and must be excluded before initiating immunosuppressive therapy. [11,18]

Acute treatment with high-dose intravenous or oral methylprednisolone (1000 mg daily for 3-5 days) accelerates recovery without altering long-term disability outcomes. [2] For severe relapses unresponsive to corticosteroids, plasma exchange represents second-line therapy. [7] Long-term relapse prevention requires disease-modifying therapies (DMTs), with annualized relapse rates reduced by 30-70% depending on agent selection and adherence. [4,10]

Key Facts

• Definition: New/worsening neurological symptoms lasting ≥24 hours, separated from prior relapse by ≥30 days, without fever/infection [1,3]
• Incidence: Untreated RRMS averages 1.0-1.3 relapses/year; DMTs reduce this by 30-70% [4,11]
• Mortality: Relapses themselves rarely fatal; MS reduces life expectancy by approximately 7-10 years [3]
• Peak age: 20-40 years (typical RRMS age range) [3]
• Sex distribution: Female:male ratio approximately 3:1 [3]
• Critical feature: Objective neurological signs consistent with CNS demyelination
• Key investigation: Clinical diagnosis; MRI with gadolinium for atypical/severe cases [3]
• First-line treatment: Methylprednisolone 1000 mg daily × 3-5 days (IV or oral) [2]
• Second-line treatment: Plasma exchange for steroid-refractory severe relapses [7]
• Prevention: Disease-modifying therapies tailored to disease activity [4,10]

Clinical Pearls

"Not all worsening is a relapse" — Pseudo-relapses account for approximately 30-40% of suspected relapses. Always exclude infection (especially UTI), fever, and metabolic stress before diagnosing true relapse. [11,18] Uhthoff phenomenon (heat-induced symptom worsening) resolves with cooling and does not require corticosteroids.

"The 24/30 rule" — True relapse requires symptoms lasting ≥24 hours (not minutes to hours) and occurring ≥30 days from previous relapse onset. This McDonald Criteria definition prevents overdiagnosis. [1]

"Oral equals intravenous for most relapses" — The COPOUSEP trial demonstrated non-inferiority of oral methylprednisolone 1000 mg daily versus IV for most relapses, improving patient convenience and reducing costs. [2] Reserve IV route for severe relapses, dysphagia, or compliance concerns.

"Steroids speed recovery, DMTs prevent relapses" — High-dose corticosteroids accelerate functional recovery by 1-2 weeks but do not alter 6-month disability outcomes or prevent future relapses. [2] DMTs are essential for long-term relapse prevention. [4,10]

"Recovery is incomplete in 20-30%" — While most patients experience significant recovery within 4-12 weeks, approximately 20-30% develop residual deficits contributing to disability accumulation. [11] Early and sustained DMT use reduces this risk.

"Pregnancy postpartum = high-risk period" — Relapse risk decreases during pregnancy (especially third trimester) but rebounds sharply in the first 3 months postpartum, with annualized relapse rate increasing 2-3 fold. [14,20] Proactive DMT resumption postpartum is critical.

Why This Matters Clinically

MS relapses represent the cardinal manifestation of relapsing-remitting MS, affecting approximately 900,000 people in the United States alone. [3] Each relapse carries risk of incomplete recovery and incremental disability accumulation, with profound impacts on employment, quality of life, and functional independence. Early recognition enables prompt corticosteroid therapy to accelerate recovery, while systematic exclusion of pseudo-relapses prevents unnecessary immunosuppression. Most critically, relapse frequency directly informs DMT selection and escalation—patients experiencing ≥2 relapses per year despite first-line therapy require escalation to higher-efficacy agents. [6,10] Neurologists, general practitioners, and emergency medicine physicians must maintain high clinical suspicion while avoiding overtreatment of pseudo-relapses.

---

2. Epidemiology

Incidence & Prevalence

Relapse Rates:

• Untreated RRMS: 1.0-1.3 relapses per year (annualized relapse rate) [11]
• First-line DMTs (interferon-beta, glatiramer acetate): Reduce relapses by 30-35% (0.6-0.9 relapses/year) [4,10]
• Moderate-efficacy DMTs (fingolimod, dimethyl fumarate): Reduce relapses by 50-55% (0.4-0.6 relapses/year) [4,10]
• High-efficacy DMTs (natalizumab, ocrelizumab, alemtuzumab): Reduce relapses by 65-70% (0.2-0.4 relapses/year) [4,10,19]
• Trend: Declining relapse rates globally due to earlier diagnosis, improved DMT access, and treat-to-target strategies [6]

MS Prevalence:

• United States: Approximately 900,000 people (285 per 100,000) [3]
• Global: 5-300 per 100,000 (latitude gradient—higher at temperate latitudes) [3]
• RRMS proportion: 85-90% of MS patients at diagnosis [3]

Demographics

Risk Factors

Non-Modifiable:

• RRMS diagnosis (defines relapsing phenotype) [3]
• Genetic susceptibility (HLA-DRB1*15:01 most strongly associated) [3]
• Female sex (higher relapse frequency) [3]

Modifiable:

Common Triggers

---

3. Pathophysiology

Molecular Pathophysiology

Phase 1: Immune Activation & CNS Infiltration

The relapse cascade initiates with peripheral immune activation, predominantly involving autoreactive CD4+ T-helper cells (Th1, Th17 subsets) that recognize myelin antigens (myelin basic protein, proteolipid protein, myelin oligodendrocyte glycoprotein). [3,6] Environmental triggers—particularly viral infections—activate these autoreactive lymphocytes via molecular mimicry and bystander activation mechanisms. [18]

Activated T-cells upregulate adhesion molecules (VLA-4, LFA-1) enabling interaction with vascular cell adhesion molecules (VCAM-1, ICAM-1) on CNS endothelium. [3,6] Matrix metalloproteinases (MMPs) degrade the extracellular matrix, facilitating transmigration across the blood-brain barrier. This process is enhanced by pro-inflammatory cytokines (IFN-γ, IL-17, TNF-α) that further increase blood-brain barrier permeability. [3,6]

Phase 2: Inflammatory Demyelination

Within the CNS parenchyma, activated T-cells encounter antigen-presenting cells (microglia, dendritic cells) displaying myelin peptides on MHC-II molecules. [3,6] This reactivates T-cells, triggering:

• Cytokine release: IFN-γ, TNF-α, IL-17 amplify local inflammation [3,6]
• B-cell activation: Plasma cells produce oligoclonal antibodies targeting myelin antigens [3]
• Macrophage activation: Phagocytose myelin debris, release reactive oxygen species and proteolytic enzymes [3,6]
• Complement activation: Membrane attack complex formation contributes to oligodendrocyte injury [3]

Demyelination results from direct immune-mediated myelin destruction, with four distinct pathological patterns (Pattern I: T-cell/macrophage; Pattern II: antibody/complement; Pattern III: distal oligodendrogliopathy; Pattern IV: primary oligodendrocyte dystrophy). [3]

Phase 3: Axonal Injury & Neurological Dysfunction

Demyelination causes conduction block (neurological symptoms) via:

• Loss of saltatory conduction at nodes of Ranvier [3]
• Sodium channel redistribution along demyelinated axons (reduced conduction velocity) [3]
• Energy failure in demyelinated axons (vulnerable to metabolic stress) [3]

Acute axonal transection occurs in approximately 30-50% of acute lesions, representing irreversible injury. [17] This "axonal loss within inflammation" drives incomplete recovery and disability accumulation. [17]

Phase 4: Resolution & Incomplete Repair

Glucocorticoid therapy (methylprednisolone) acts via:

• Glucocorticoid receptor binding inducing anti-inflammatory gene transcription [12]
• Suppression of NF-κB pathway (reduced cytokine production) [12]
• Stabilization of blood-brain barrier [12]
• Induction of T-cell apoptosis [12]
• Metabolic rewiring toward anti-inflammatory phenotypes [12]

Endogenous resolution mechanisms include:

• Regulatory T-cell (Treg) expansion suppressing effector responses [3,6]
• Anti-inflammatory cytokine shift (IL-10, TGF-β) [3,6]
• Partial remyelination by oligodendrocyte precursor cells (incomplete in most lesions) [3]

Recovery reflects combination of:

• Inflammation resolution (symptom improvement within days-weeks)
• Partial remyelination (weeks-months)
• Neuroplasticity and functional reorganization (months)

Incomplete recovery occurs due to:

• Persistent axonal loss (irreversible) [17]
• Inefficient remyelination [3]
• Ongoing chronic inflammation (smoldering plaques) [21,22]

Classification by Relapse Type

Pseudo-Relapse Mechanisms

---

4. Clinical Presentation

Symptoms: The Patient's Story

Typical Relapse Narrative:

Patients report subacute onset (hours to days) of new neurological symptoms or worsening of prior symptoms beyond usual fluctuations. [1,3] The "24-hour rule" is critical—transient symptoms lasting less than 24 hours generally do not qualify as relapses. [1] Patients must be afebrile and without concurrent infection to meet true relapse criteria. [1,11]

Common Presentations by Syndrome:

1. Optic Neuritis (20-30% of relapses) [5]

• Visual symptoms: Unilateral vision loss (blurred vision progressing to severe visual impairment over days), scotoma (central or paracentral visual field defect), impaired color vision (red desaturation)
• Pain: Periocular pain, worse with eye movement (90% of cases) [5]
• Timing: Vision loss progresses over 1-7 days, plateaus, then gradually improves over weeks-months [5]
• Red flags: Bilateral simultaneous vision loss (suggests NMOSD or MOGAD rather than MS), severe disc edema, no pain, absent light perception [5,8]

2. Partial Transverse Myelitis (30-40% of relapses) [3,8]

• Motor: Weakness in lower limbs (paraparesis) or all four limbs if cervical (quadriparesis), typically incomplete and asymmetric
• Sensory: Ascending sensory symptoms from feet upward, sensory level (band-like tightness), paresthesias, dysesthesias
• Autonomic: Bladder urgency, frequency, or retention (most common); bowel dysfunction less common
• Lhermitte sign: Electric shock sensation down spine with neck flexion (indicates cervical cord involvement)
• Timing: Symptoms evolve over hours to days, nadir typically within 1-2 weeks [8]
• Red flags: Complete sensory/motor level, longitudinally extensive transverse myelitis (≥3 vertebral segments—suggests NMOSD/MOGAD) [7,8]

3. Brainstem Syndrome (15-25% of relapses) [3]

• Ocular motility: Internuclear ophthalmoplegia (adduction deficit with contralateral abduction nystagmus—pathognomonic for MLF lesion), diplopia, nystagmus
• Vestibular: Vertigo, imbalance, nausea
• Cranial nerve: Facial weakness, trigeminal neuralgia, dysarthria, dysphagia
• Timing: Acute onset over hours to days [3]

4. Cerebellar Syndrome (10-20% of relapses) [3]

• Coordination: Ataxia, dysmetria (past-pointing on finger-nose-finger), dysdiadochokinesia
• Tremor: Intention tremor, kinetic tremor
• Gait: Wide-based ataxic gait, tendency to fall
• Speech: Scanning dysarthria
• Timing: Subacute onset [3]

5. Cerebral Syndrome (Variable) [3]

• Motor/Sensory: Hemiparesis, hemisensory loss
• Cognitive: Executive dysfunction, memory impairment, processing speed reduction
• Seizures: Uncommon but possible with cortical lesions
• Timing: Subacute [3]

Signs: What You See

Vital Signs:

Neurological Examination Findings:

Cranial Nerves:

Motor Examination:

Sensory Examination:

Coordination & Gait:

Disability Assessment:

Red Flags

[!CAUTION] Red Flags — Immediate Escalation Required:

Diagnostic Red Flags (Suggest Alternative Diagnosis):

• Longitudinally extensive transverse myelitis (≥3 vertebral segments on MRI) → Consider NMOSD [7] or MOGAD [8]; test AQP4-IgG and MOG-IgG
• Bilateral simultaneous optic neuritis → Consider NMOSD or MOGAD [5,7,8]
• Severe optic disc edema → Consider MOGAD [8]; atypical for MS
• Encephalopathy/confusion → Consider cerebral NMOSD, ADEM, or non-MS etiology [7,8]
• Fever or signs of infection → Pseudo-relapse until proven otherwise; exclude UTI, respiratory infection [11,18]

Severity Red Flags (Require Urgent Treatment):

• Respiratory compromise (high cervical myelitis affecting diaphragm) → ICU monitoring
• Complete spinal cord syndrome (complete sensory/motor level) → Consider plasma exchange early if steroid-refractory [7]
• No light perception vision loss → Aggressive treatment; consider plasma exchange [5,7]
• Rapidly progressive symptoms over hours → May indicate fulminant inflammatory demyelination; urgent MRI and high-dose steroids [3]

---

5. Clinical Examination

Structured Approach: ABCDE

A - Airway

• Assessment: Patent in vast majority
• Red Flag: Bulbar weakness (dysphagia, dysarthria) suggests brainstem involvement—assess aspiration risk

B - Breathing

• Assessment: SpO₂, respiratory rate, work of breathing
• Red Flag: Respiratory compromise if high cervical cord involvement (C3-C5 affecting phrenic nerve) → Requires ICU monitoring, consider mechanical ventilation

C - Circulation

• Assessment: Heart rate, blood pressure
• Finding: Usually normal; autonomic dysfunction uncommon in acute relapses

D - Disability

• Assessment: Focused neurological examination (see below)
• Quantify: EDSS score to document disability level [16]

E - Exposure

• Assessment: Complete neurological examination
• Look for: Signs of infection (fever, costovertebral angle tenderness, respiratory signs) that suggest pseudo-relapse [11,18]

Comprehensive Neurological Examination

1. Mental Status

• Level of consciousness: Alert (encephalopathy is red flag for non-MS etiology)
• Cognition: Assess orientation, memory, attention (cognitive relapses rare but possible)

2. Cranial Nerves (Detailed)

• Visual acuity (Snellen chart): Quantify vision loss in optic neuritis [5]
• Ishihara plates: Assess color vision (red desaturation in optic neuritis) [5]
• Visual fields: Confrontation testing; central/paracentral scotoma in optic neuritis [5]
• Pupils: RAPD (relative afferent pupillary defect) in optic neuritis (Marcus Gunn pupil) [5]
• Fundoscopy: Optic disc appearance (usually normal or mild swelling in MS optic neuritis; severe swelling suggests MOGAD) [5,8]
• Ocular motility: INO, diplopia, nystagmus [3]
• Facial sensation/strength: Trigeminal/facial nerve involvement [3]

3. Motor

• Inspection: Muscle bulk (atrophy develops in chronic weakness, not acute relapse), fasciculations (absent—MS is UMN)
• Tone: Spasticity (velocity-dependent increased tone) vs rigidity
• Power: MRC grading 0-5 in all limb groups; document pyramidal pattern weakness
• Reflexes: Deep tendon reflexes (hyperreflexia in UMN lesions), clonus (sustained ankle clonus in spinal cord lesions)
• Plantar response: Babinski sign (extensor plantar = UMN lesion)

4. Sensory

• Light touch/pinprick: Map sensory level if myelitis suspected [8]
• Vibration: 128 Hz tuning fork at bony prominences (dorsal column function)
• Proprioception: Finger/toe position sense
• Lhermitte sign: Electric shock down spine with neck flexion (cervical cord lesion) [3]

5. Coordination

• Finger-nose-finger: Dysmetria, intention tremor [3]
• Heel-shin: Ataxia [3]
• Rapid alternating movements: Dysdiadochokinesia [3]

6. Gait

• Normal gait: Observe base, symmetry, arm swing
• Tandem gait: Assess cerebellar/proprioceptive function
• Romberg test: Eyes open vs closed (positive = proprioceptive dysfunction)

7. Special Tests

---

6. Investigations

First-Line (Bedside) - Do Immediately

1. Clinical Diagnosis (Usually Sufficient) [1,3]

Relapse diagnosis is primarily clinical based on McDonald Criteria: [1]

• New or worsening neurological symptoms typical of CNS inflammatory demyelination
• Duration ≥24 hours (excludes transient fluctuations)
• Separated by ≥30 days from previous relapse onset (prevents double-counting prolonged single attacks)
• Absence of fever or infection (excludes pseudo-relapses) [11]
• Objective neurological signs on examination consistent with symptoms

Action: Most relapses can be diagnosed and treated on clinical grounds without urgent MRI. [1,3]

2. Exclude Infection (Critical) [11,18]

Critical Point: Approximately 30-40% of suspected relapses are pseudo-relapses triggered by infection. [11] Treating infection often resolves symptoms without need for corticosteroids. [11,18]

Laboratory Tests

Imaging

MRI Brain ± Spine with Gadolinium [3]

Indications for MRI:

• Atypical presentation (suggests alternative diagnosis—NMOSD, MOGAD, CNS vasculitis)
• Severe relapse (complete myelitis, no light perception vision loss—may influence decision for plasma exchange)
• Diagnostic uncertainty (confirm new inflammatory activity vs pseudo-relapse)
• Baseline for clinical trial or treatment escalation decisions

Timing: MRI not required emergently for typical relapse; can be performed within days to weeks if needed. [3]

MRI Findings in MS Relapse:

Red Flag MRI Findings (Suggest Non-MS Diagnosis):

• Longitudinally extensive transverse myelitis (≥3 vertebral segments) → NMOSD or MOGAD [7,8]
• Area postrema lesion → NMOSD [7]
• Tumefactive lesions (> 2 cm) → Consider tumefactive MS, CNS lymphoma, glioma [3]
• Corpus callosum involvement with "fluffy" lesions → MOGAD [8]

Diagnostic Criteria

McDonald Criteria for MS Relapse (Simplified) [1,3]

A relapse is defined by:

1. Patient-reported symptoms or objectively observed signs typical of acute inflammatory demyelinating CNS event
2. Duration ≥24 hours
3. Absence of fever or infection
4. Separated by ≥30 days from previous relapse onset

Dissemination in Time (DIT): [1]

• Simultaneous presence of gadolinium-enhancing (active) and non-enhancing (older) lesions on MRI, OR
• New T2 or gadolinium-enhancing lesion on follow-up MRI compared to baseline, OR
• Clinical relapse occurring ≥30 days after initial clinical event

Dissemination in Space (DIS): [1]

• ≥1 T2 lesion in ≥2 of 4 CNS regions: periventricular, juxtacortical, infratentorial, spinal cord

Pseudo-Relapse vs True Relapse Differentiation [11]

Severity Assessment

---

7. Management

Management Algorithm

        SUSPECTED MS RELAPSE
    (New/worsening symptoms ≥24h)
                    ↓
┌──────────────────────────────────────────────────┐
│         EXCLUDE PSEUDO-RELAPSE (CRITICAL)        │
│  • Check temperature (fever?)                    │
│  • Urine dipstick (UTI?)                         │
│  • Assess for infection (respiratory, skin, etc.)│
│  • Recent heat exposure? (Uhthoff phenomenon)    │
│                                                  │
│  IF INFECTION PRESENT:                           │
│  → Treat infection first                         │
│  → Reassess after 48h of treatment               │
│  → If symptoms persist → True relapse            │
│                                                  │
│  IF HEAT-RELATED (Uhthoff):                      │
│  → Cooling measures                              │
│  → Symptoms resolve without steroids             │
└──────────────────────────────────────────────────┘
                    ↓
          TRUE RELAPSE CONFIRMED
                    ↓
┌──────────────────────────────────────────────────┐
│         ASSESS SEVERITY & IMPACT                 │
├──────────────────────────────────────────────────┤
│  MILD (minimal functional impact):               │
│  → Patient preference: treat vs observe          │
│  → If treat: Oral methylprednisolone 1000mg      │
│     × 3-5 days                                   │
│  → Outpatient management                         │
│                                                  │
│  MODERATE (significant functional impact):       │
│  → Oral methylprednisolone 1000mg × 3-5 days     │
│     (non-inferior to IV) [COPOUSEP trial]        │
│  → Outpatient management with close follow-up    │
│                                                  │
│  SEVERE (unable to perform ADLs, hospitalization):│
│  → Admit to hospital                             │
│  → IV methylprednisolone 1000mg × 3-5 days       │
│  → Supportive care, rehabilitation               │
│  → Consider MRI if not recently done             │
└──────────────────────────────────────────────────┘
                    ↓
┌──────────────────────────────────────────────────┐
│         CORTICOSTEROID TREATMENT                 │
│                                                  │
│  FIRST-LINE: Methylprednisolone [2]              │
│  • IV or ORAL 1000 mg daily × 3-5 days           │
│    (COPOUSEP: oral non-inferior to IV)           │
│  • No taper needed after 3-5 day course          │
│  • Mechanism: Reduces inflammation, stabilizes   │
│    blood-brain barrier, speeds recovery [12]     │
│  • Note: Speeds recovery by 1-2 weeks but does   │
│    NOT alter 6-month disability outcome [2]      │
│                                                  │
│  SUPPORTIVE:                                     │
│  • PPI (omeprazole 20mg) for GI protection       │
│  • Monitor glucose if diabetic                   │
│  • Educate on insomnia, mood changes (common)    │
└──────────────────────────────────────────────────┘
                    ↓
       REASSESS AT 5-7 DAYS POST-STEROIDS
                    ↓
┌──────────────────────────────────────────────────┐
│    IF IMPROVING (70-80% of cases [2,11]):        │
│    → Continue rehabilitation                     │
│    → Symptom management (see below)              │
│    → DMT review and optimization                 │
└──────────────────────────────────────────────────┘
                    ↓
┌──────────────────────────────────────────────────┐
│    IF NO IMPROVEMENT OR WORSENING (20-30%):      │
│    → Consider PLASMA EXCHANGE (PLEX) [7]         │
│                                                  │
│    PLEX Indications:                             │
│    • Severe relapse unresponsive to steroids     │
│    • Complete spinal cord syndrome               │
│    • No light perception vision loss             │
│    • Life-threatening relapse                    │
│                                                  │
│    PLEX Protocol:                                │
│    • 5-7 exchanges over 10-14 days               │
│    • 1.0-1.5 plasma volumes per exchange         │
│    • Response rate: 40-60% in steroid-refractory │
│      cases [7]                                   │
└──────────────────────────────────────────────────┘
                    ↓
┌──────────────────────────────────────────────────┐
│         SYMPTOM MANAGEMENT (ONGOING)             │
│  • Spasticity: Baclofen, tizanidine              │
│  • Neuropathic pain: Gabapentin, pregabalin      │
│  • Bladder dysfunction: Anticholinergics,        │
│    intermittent self-catheterization             │
│  • Fatigue: Amantadine, energy conservation      │
│  • Rehabilitation: PT, OT, neuro-rehab           │
└──────────────────────────────────────────────────┘
                    ↓
┌──────────────────────────────────────────────────┐
│         PREVENT FUTURE RELAPSES (CRITICAL)       │
│                                                  │
│  DMT REVIEW AND OPTIMIZATION [4,10]:             │
│  • Ensure patient on appropriate DMT             │
│  • Assess adherence                              │
│  • Assess treatment response:                    │
│    - No relapses on current DMT = continue       │
│    - ≥1 relapse/year despite DMT = ESCALATE      │
│    - ≥2 relapses/year = URGENT ESCALATION        │
│                                                  │
│  ESCALATION STRATEGY [6,10]:                     │
│  • First-line → Moderate-efficacy (fingolimod,   │
│    dimethyl fumarate)                            │
│  • Moderate-efficacy → High-efficacy             │
│    (natalizumab, ocrelizumab, alemtuzumab)       │
│                                                  │
│  LIFESTYLE MODIFICATIONS:                        │
│  • Infection avoidance/prompt treatment [18]     │
│  • Heat avoidance strategies [11]                │
│  • Stress management                             │
│  • Smoking cessation [3]                         │
│  • Vitamin D supplementation (2000-4000 IU/day)  │
└──────────────────────────────────────────────────┘
                    ↓
┌──────────────────────────────────────────────────┐
│         FOLLOW-UP & MONITORING                   │
│  • Clinical review 4-6 weeks post-relapse        │
│  • Assess recovery (EDSS scoring) [16]           │
│  • MRI at 3-6 months if treatment escalation     │
│    being considered                              │
│  • Long-term: Annual neurology review, MRI       │
│    surveillance per local protocols              │
└──────────────────────────────────────────────────┘

Acute/Emergency Management - The First Hour

Immediate Actions (Do Simultaneously):

1. Exclude Pseudo-Relapse (PRIORITY) [11,18]

• Urine dipstick: Check for UTI (leucocytes, nitrites, blood)
• Temperature: Document fever (suggests infection)
• History: Recent infection? Heat exposure? Exertion?
• Action: If infection suspected, send urine culture, start antibiotics, reassess in 48h [11,18]

2. Assess Severity

• Functional impact: Can patient walk? Perform ADLs? Work?
• EDSS scoring: Document baseline and current EDSS [16]
• Red flags: Respiratory compromise? Complete spinal cord syndrome? No light perception vision loss?
• Action: Determine inpatient vs outpatient management; identify need for plasma exchange [7]

3. Initiate Corticosteroids (If True Relapse and Moderate-Severe) [2]

Mechanism of Action [12]:

• Glucocorticoid receptor activation → anti-inflammatory gene transcription
• NF-κB pathway suppression → reduced cytokine production (TNF-α, IL-1β, IL-6)
• Blood-brain barrier stabilization → reduced immune cell infiltration
• T-cell apoptosis → reduced autoreactive lymphocytes
• Metabolic rewiring toward anti-inflammatory phenotypes

Evidence [2]:

• COPOUSEP trial (2015): Oral methylprednisolone 1000 mg × 3 days non-inferior to IV for treatment of MS relapses (primary endpoint: proportion improved at day 28 without retreatment)
• Accelerates recovery by 1-2 weeks vs placebo
• Does NOT alter 6-month disability outcomes (important patient counseling point)
• Does NOT prevent future relapses (DMTs required for prevention)

4. Supportive Care

• Hydration: IV fluids if severe, unable to drink
• VTE prophylaxis: If immobile (LMWH)
• Bladder care: Assess post-void residual if urinary retention; intermittent catheterization if needed
• Mobility: Early mobilization with physiotherapy

Medical Management

First-Line: High-Dose Corticosteroids [2]

Alternative Regimens (Less Commonly Used):

• Dexamethasone 160 mg/day × 3-5 days (oral or IV—longer half-life than methylprednisolone)
• Prednisolone 500-1000 mg/day (oral—if methylprednisolone unavailable)

Taper: Not required after 3-5 day pulse therapy (short duration prevents hypothalamic-pituitary-adrenal axis suppression). [2] Prolonged tapers (e.g., 2-week oral prednisolone taper) are outdated and not evidence-based.

Patient Counseling:

• Expected timeline: Improvement typically begins within 3-7 days; maximal recovery at 4-12 weeks [11]
• Side effects: Insomnia (dose in morning), mood changes/euphoria, hyperglycemia (monitor if diabetic), GI upset (take with food + PPI)
• Long-term outcome: Steroids speed recovery but do not change 6-month disability or prevent future relapses [2]

Second-Line: Plasma Exchange (PLEX) [7]

Alternative Emerging Therapies:

• Immunoadsorption: Similar to PLEX but more selective removal of antibodies; limited availability
• High-dose cyclophosphamide: Reserved for fulminant relapses unresponsive to steroids + PLEX (rare, expert centers only)

Symptom Management (Ongoing)

Disease-Modifying Therapies (DMTs) - Prevention [4,10]

Critical Principle: Corticosteroids treat acute relapses; DMTs prevent future relapses. [4,10]

First-Line (Moderate Efficacy - 30-35% Relapse Reduction):

• Interferon beta-1a (Avonex IM weekly, Rebif SC TIW)
• Interferon beta-1b (Betaseron/Extavia SC EOD)
• Glatiramer acetate (Copaxone SC daily or TIW)
• Teriflunomide (Aubagio oral 14 mg daily)

Moderate Efficacy (50-55% Relapse Reduction):

• Dimethyl fumarate (Tecfidera oral 240 mg BD)
• Fingolimod (Gilenya oral 0.5 mg daily)
• Sphingosine-1-phosphate receptor modulators (Ozanimod, Ponesimod)

High Efficacy (65-70% Relapse Reduction):

• Natalizumab (Tysabri IV 300 mg monthly) — PML risk (JC virus monitoring required)
• Ocrelizumab (Ocrevus IV 600 mg every 6 months) — CD20-depleting anti-B-cell
• Alemtuzumab (Lemtrada IV courses) — CD52-depleting; high efficacy but autoimmune risks
• Cladribine (Mavenclad oral courses) — Lymphocyte-depleting

DMT Selection Principles [6,10]:

• Escalation approach: Start first-line, escalate if breakthrough relapses (≥1 relapse/year on treatment)
• Early high-efficacy approach: Start high-efficacy DMT in aggressive disease (≥2 relapses in first year, high T2 lesion load, severe relapses)
• Switching criteria: ≥1 relapse/year, new/enlarging T2 lesions, EDSS progression despite treatment

Pregnancy Considerations [14,20]:

• Relapse risk: Decreases 60-70% during pregnancy (especially trimester 3), rebounds 2-3× in first 3 months postpartum [14,20]
• Management: Discontinue most DMTs pre-conception; consider glatiramer acetate or interferons if high disease activity; resume DMT promptly postpartum (within weeks if not breastfeeding) [14,20]
• Relapse treatment in pregnancy: High-dose steroids generally safe after first trimester; avoid in first trimester if possible
• Breastfeeding: Most DMTs contraindicated during breastfeeding; individualized risk-benefit discussion [20]

Disposition

Admit to Hospital If:

• Severe functional impairment (unable to mobilize independently, unable to perform ADLs)
• Requiring IV corticosteroids with compliance concerns or social support issues
• Respiratory compromise (high cervical myelitis)
• Complete spinal cord syndrome (may require plasma exchange)
• Severe vision loss (no light perception)
• Inability to manage bladder (urinary retention requiring catheterization training)
• Social circumstances preclude safe outpatient management

Ward: Neurology ward (ideally with neuro-rehabilitation support)

Outpatient Management:

• Mild-moderate relapses suitable for outpatient oral steroids [2]
• Ensure follow-up within 1 week (neurology clinic or GP)
• Provide relapse action plan, emergency contact numbers
• Arrange physiotherapy, occupational therapy as needed

Discharge Criteria:

• Stable or improving neurological symptoms
• Completed corticosteroid course or can safely complete at home
• Safe mobility (with aids if needed)
• Bladder management plan in place
• Neurology follow-up arranged

Follow-Up:

• Acute phase: Neurology review at 4-6 weeks post-relapse to assess recovery
• 3 months: Clinical assessment ± MRI to assess treatment response
• Ongoing: 6-12 monthly neurology review with annual MRI (per local protocols)
• DMT monitoring: As per specific DMT protocols (e.g., natalizumab JC virus monitoring, ocrelizumab immunoglobulin levels)

---

8. Complications

Immediate (Days-Weeks)

Early (Weeks-Months)

1. Further Relapses (If Suboptimal DMT) [4,10,11]

• Incidence: 50-70% within 1 year if untreated; 15-30% within 1 year on first-line DMTs [4,10]
• Mechanism: Ongoing disease activity despite current DMT
• Management: DMT escalation if ≥1 relapse/year on treatment [6,10]
• Prevention: High-efficacy DMTs reduce relapse risk by 65-70% [4,10,19]

2. Disability Accumulation (Relapse-Associated Worsening, RAW) [17]

• Incidence: Each relapse carries ~20-30% risk of incomplete recovery [11]
• Mechanism: Acute axonal transection during relapse, irreversible axonal loss [17]
• Impact: Stepwise disability progression (distinct from slow PIRA—progression independent of relapse activity) [17]
• Management: Relapse prevention (DMTs), neuro-rehabilitation to maximize compensation
• Prevention: Early aggressive DMT to minimize relapse frequency [4,10]

3. Secondary Complications of Disability

• Deconditioning: Prolonged immobility → muscle atrophy, contractures
• Falls: Ataxia, weakness → fracture risk (especially if long-term corticosteroid use causes osteoporosis)
• Pressure ulcers: Immobility, sensory loss → skin breakdown
• Recurrent UTIs: Neurogenic bladder → chronic bacteriuria, pyelonephritis
• Depression: Disease burden, functional impairment → major depression (30-50% prevalence in MS) [3]

Late (Months-Years)

1. Conversion to Secondary Progressive MS (SPMS) [21,22]

• Incidence: 20-30% of RRMS patients transition to SPMS over 10-20 years (highly variable) [21]
• Definition: Gradual neurological decline independent of relapses, with or without superimposed relapses [21,22]
• Mechanism: Shift from focal inflammatory relapses to chronic compartmentalized inflammation, neurodegeneration [21,22]
• Clinical features: Progressive spastic paraparesis, progressive cognitive decline, reduced/absent relapses [21,22]
• Management: Limited DMT options (ocrelizumab, siponimod show modest benefit); focus on symptom management, rehabilitation [21,22]
• Prevention: Early high-efficacy DMT may delay transition to SPMS [21,22]

2. Cumulative Disability (EDSS Progression) [16,17]

• Natural history: Untreated RRMS reaches EDSS 6.0 (requires walking aid) at median 15-20 years from onset [17]
• Impact of DMTs: High-efficacy DMTs delay disability milestones by 3-5 years [4,10]
• Irreversible disability: Once EDSS ≥6.0, significant neurological reserve lost; DMT benefit diminishes [17]

---

9. Prognosis & Outcomes

Natural History (Without Treatment)

Untreated RRMS Relapse Outcomes:

• Spontaneous recovery: 60-70% of relapses show partial-to-complete recovery even without treatment over 3-6 months [11]
• Incomplete recovery: 30-40% have residual deficits at 6 months [11]
• Disability accumulation: Median time to EDSS 6.0 (walking aid required) = 15-20 years from onset [17]
• Mortality: MS reduces life expectancy by 7-10 years vs general population (primary causes: infection, complications of disability) [3]

Outcomes with Treatment

Short-Term (Relapse Recovery) [2,11]:

Long-Term (Disease Course with DMTs) [4,10]:

Factors Affecting Recovery:

Good Prognosis:

• Young age (less than 40 years at relapse): Better neurological reserve, greater recovery capacity [11]
• Sensory/optic neuritis relapse: Typically good recovery (90% regain functional vision in optic neuritis) [5,11]
• First relapse: Higher likelihood of complete recovery vs subsequent relapses [11]
• Early corticosteroid treatment (within 2 weeks of onset): Faster recovery [2]
• Low baseline EDSS (less than 3.0): Greater neurological reserve [16]

Poor Prognosis:

• Older age (> 50 years at relapse): Reduced recovery capacity, higher risk of incomplete recovery [11]
• Motor/cerebellar relapse: Lower complete recovery rates; tremor often persists [11]
• Complete spinal cord syndrome: High risk of permanent disability [8]
• Delayed treatment (> 4 weeks from onset): Reduced steroid efficacy [2]
• High baseline EDSS (≥6.0): Limited neurological reserve, greater risk of permanent worsening [16]
• High relapse frequency (≥2/year): Accelerated disability accumulation [17]

Prognostic Factors

Special Populations

Pregnancy/Postpartum [14,20]:

• Pregnancy: Relapse risk decreases 60-70% (especially trimester 3) due to pregnancy-induced immunotolerance [14,20]
• Postpartum: Relapse risk rebounds 2-3× in first 3 months postpartum [14,20]
• Prognosis: Pregnancy does not worsen long-term disability outcomes; postpartum relapses have similar recovery to non-pregnancy relapses [20]
• Management: Resume DMT promptly postpartum to mitigate rebound risk [14,20]

Pediatric-Onset MS:

• Recovery: Generally better recovery from individual relapses (greater neuroplasticity) [9]
• Long-term: Reaches disability milestones at younger chronological age (longer disease duration) [9]

---

10. Evidence & Guidelines

Key Guidelines

1. McDonald Criteria (2017 Revision) [1]

• Organization: International Panel on MS Diagnosis
• Citation: McDonald WI, et al. Ann Neurol. 2001;50(1):121-127. DOI: 10.1002/ana.1032
• Key Points:
  • "Relapse definition: ≥24 hours duration, ≥30 days from previous relapse, no fever/infection"
  • "Dissemination in time (DIT): New T2/Gad+ lesions on follow-up MRI, or simultaneous Gad+/non-enhancing lesions"
  • "Dissemination in space (DIS): Lesions in ≥2 of 4 CNS regions (periventricular, juxtacortical, infratentorial, spinal)"
• Evidence Level: 1A (International consensus, validated in multiple cohorts)

2. NICE Guideline NG220: Multiple Sclerosis in Adults (2022)

• Organization: National Institute for Health and Care Excellence (UK)
• Key Recommendations:
  • High-dose methylprednisolone (500-1000 mg daily × 3-5 days) for relapses causing functional impairment
  • Oral route acceptable alternative to IV
  • DMTs should be offered to reduce relapse frequency and delay disability
• Evidence Level: 1A (Systematic review and RCT evidence)

3. AAN Practice Guideline: Disease-Modifying Therapies for MS (2018) [10]

• Citation: Rae-Grant A, et al. Neurology. 2018;90(17):777-788. DOI: 10.1212/WNL.0000000000005347
• Key Recommendations:
  • Offer DMTs to patients with relapsing MS (strong recommendation)
  • Higher-efficacy DMTs more effective than lower-efficacy for relapse reduction (high-quality evidence)
  • Individualize DMT selection based on efficacy, safety, patient preference
• Evidence Level: 1A (Systematic review and meta-analysis)

4. ECTRIMS/EAN Guideline: Treatment of MS (2018)

• Organization: European Committee for Treatment and Research in Multiple Sclerosis / European Academy of Neurology
• Key Points: DMT selection, escalation vs early high-efficacy strategies, monitoring protocols
• Evidence Level: 1A

Landmark Trials

1. COPOUSEP Trial (2015) [2]

• Citation: Le Page E, et al. Lancet. 2015;386(9997):974-981. DOI: 10.1016/S0140-6736(15)61137-0
• Design: Multicentre, double-blind, randomized, non-inferiority trial (n=199)
• Intervention: Oral methylprednisolone 1000 mg daily × 3 days vs IV methylprednisolone 1000 mg daily × 3 days
• Primary Outcome: Proportion improved at day 28 (≥1 point decrease in most affected Functional System Score) without retreatment
• Results: Oral non-inferior to IV (primary endpoint 71.7% oral vs 71.4% IV; non-inferiority margin met)
• Clinical Impact: Oral route acceptable for most MS relapses; improves convenience, reduces costs
• Evidence Level: 1A (RCT)

2. Cochrane Network Meta-Analysis: DMTs for RRMS (2024) [4]

• Citation: Gonzalez-Lorenzo M, et al. Cochrane Database Syst Rev. 2024;1:CD011381. DOI: 10.1002/14651858.CD011381.pub3
• Design: Network meta-analysis of 50+ RCTs (> 30,000 participants)
• Interventions: 20+ DMTs vs placebo/active comparator
• Outcomes: Relapse rate, disability progression, adverse events
• Key Findings:
  • High-efficacy DMTs (natalizumab, ocrelizumab, alemtuzumab) reduce relapses by 65-70% vs placebo
  • First-line DMTs (interferon-beta, glatiramer) reduce relapses by 30-35% vs placebo
  • Trade-off between efficacy and safety (higher-efficacy agents have greater adverse event risk)
• Clinical Impact: Informs DMT selection hierarchy
• Evidence Level: 1A (Network meta-analysis of RCTs)

3. Optic Neuritis Treatment Trial (ONTT) (1992)

• Design: Multicenter RCT (n=457)
• Intervention: IV methylprednisolone vs oral prednisone vs placebo
• Results: IV methylprednisolone accelerated visual recovery vs placebo; oral prednisone alone increased recurrence risk (not recommended)
• Clinical Impact: Established high-dose IV steroids (not oral prednisone alone) as standard for optic neuritis
• Evidence Level: 1A (RCT)

4. Multiple Sclerosis Pregnancy & Postpartum Studies [14,20]

• Citations:
  • "Gavoille A, et al. JAMA Neurol. 2025. DOI: 10.1001/jamaneurol.2025.2550 [14]"
  • "Schubert C, et al. J Neurol Neurosurg Psychiatry. 2023. DOI: 10.1136/jnnp-2022-330533 [20]"
• Design: Systematic reviews and meta-analyses
• Key Findings:
  • Relapse risk decreases 60-70% during pregnancy (especially trimester 3)
  • Postpartum relapse risk increases 2-3× in first 3 months
  • Early DMT resumption postpartum reduces rebound relapse risk
• Clinical Impact: Informs pregnancy planning, DMT discontinuation/resumption timing
• Evidence Level: 1A-2A (Systematic reviews, prospective cohorts)

Evidence Strength Summary

---

10A. Differential Diagnosis

Key Differentials by Presentation

Acute Optic Neuropathy:

Acute Myelopathy:

Acute Brainstem Syndrome:

Red Flag Differentials Requiring Urgent Alternative Diagnosis

When to Suspect NOT MS:

Diagnostic Approach to Suspected MS Relapse

Step 1: Confirm Clinical Relapse Criteria [1,3]

• ✅ New/worsening neurological symptoms lasting ≥24 hours?
• ✅ Objective neurological signs on examination?
• ✅ Symptoms separated by ≥30 days from previous relapse onset?
• ✅ Afebrile and no signs of infection?

Step 2: Exclude Pseudo-Relapse [11,18]

• 🔍 Check temperature, urine dipstick, signs of infection
• 🔍 Recent heat exposure, exercise, stress?
• 🔍 New medications (sodium channel blockers can worsen symptoms)?
• ⚠️ If infection present: Treat infection first; reassess at 48 hours

Step 3: Assess for Red Flag Features Suggesting Alternative Diagnosis

• 🚩 Fever, altered consciousness → infection/encephalitis
• 🚩 Severe back pain, sphincter dysfunction → spinal cord compression
• 🚩 Sudden onset over minutes → stroke
• 🚩 Bilateral simultaneous ON, LETM → NMOSD/MOGAD
• 🚩 Severe disc edema → MOGAD

Step 4: If Red Flags Present, Investigate Alternative Diagnoses

• MRI brain ± spine with gadolinium
• Lumbar puncture (CSF analysis, OCB, infectious workup, autoimmune panel)
• Serology: AQP4-IgG, MOG-IgG if atypical features [7,8]
• Infectious workup if fever/systemic illness

Step 5: Confirm MS Diagnosis if Not Already Established [1]

• MRI brain: DIS (≥2 of 4 CNS regions) and DIT (new T2/Gad+ lesions or simultaneous Gad+/non-enhancing lesions)
• Lumbar puncture: CSF oligoclonal bands (present in ~95% MS patients)
• Exclude MS mimics (NMOSD, MOGAD, CNS vasculitis, sarcoidosis, Behçet's, infectious)

---

10B. Exam Viva Scenarios

Scenario 1: Suspected MS Relapse with Infection

Viva Stem: "A 32-year-old woman with established relapsing-remitting MS (on dimethyl fumarate for 2 years) presents to the neurology clinic with 3 days of worsening leg weakness and urinary urgency. She mentions burning when passing urine for the past week. On examination, she has MRC grade 4/5 weakness in both legs, brisk knee reflexes, and bilateral upgoing plantars. She is afebrile. What is your approach?"

Model Answer:

1. Clinical Assessment:

• "This could be a true MS relapse presenting with spinal cord involvement (bilateral leg weakness, pyramidal signs, bladder symptoms), but the concurrent urinary symptoms raise concern for UTI-related pseudo-relapse."
• "I would first differentiate pseudo-relapse from true relapse by:
  • "History: Is this worsening of pre-existing symptoms or new symptoms? Duration ≥24 hours? Previous similar episodes with infection?"
  • "Examination: Objectively document neurological deficit and quantify with EDSS"
  • Exclude infection: Urine dipstick immediately (leucocytes, nitrites, blood), temperature, CRP"

2. Immediate Investigations:

• "Urine dipstick + culture (most important—30-40% of suspected relapses are infection-related pseudo-relapses [11,18])"
• "Temperature, CRP (if elevated → infection)"
• "Clinical diagnosis sufficient if typical relapse; MRI not urgently needed unless atypical features"

3. Management Decision Tree:

• "If urine dipstick positive:

  • Treat UTI first (empirical antibiotics—trimethoprim or nitrofurantoin)
  • "Reassess at 48 hours: if symptoms resolve → pseudo-relapse, no steroids needed [11,18]"
  • If symptoms persist despite infection treatment → true relapse (concurrent UTI + relapse), proceed with steroids"

• "If urine dipstick negative (true relapse):

  • "High-dose methylprednisolone 1000 mg daily × 3-5 days (oral vs IV: oral acceptable per COPOUSEP trial [2])"
  • "Symptom management (bladder urgency: anticholinergics if not in retention)"
  • DMT review: 2-year disease stability on dimethyl fumarate, so likely continue current DMT unless frequent relapses (would then escalate)"

4. Examiner Probes:

Q: "Why is excluding infection so critical before giving steroids?"

• "Steroids are immunosuppressive and can worsen infections. Additionally, infections commonly cause pseudo-relapses (transient symptom worsening via cytokine-induced conduction block in demyelinated axons [11,18]), which resolve with infection treatment alone, avoiding unnecessary steroid exposure and side effects."

Q: "What if the patient has had 3 relapses in the past year despite dimethyl fumarate?"

• "This indicates treatment failure (≥1 relapse/year on DMT suggests suboptimal disease control [6,10]). I would:
  • Treat the current relapse with steroids
  • Escalate DMT to high-efficacy agent (natalizumab, ocrelizumab, alemtuzumab) after discussion of risks/benefits
  • Consider MRI to assess new lesion burden and confirm ongoing disease activity"

---

Scenario 2: Severe Steroid-Refractory Relapse

Viva Stem: "A 28-year-old man with MS presents with acute onset of severe bilateral leg weakness, numbness to T6 level, and urinary retention. He received IV methylprednisolone 1g daily for 5 days, but 7 days post-treatment there is no improvement—he remains unable to walk (EDSS 8.0, was 2.0 baseline). MRI spine shows extensive T2 hyperintensity C5-T8 with gadolinium enhancement. What are your considerations and next steps?"

Model Answer:

1. Severity Assessment:

• "This is a severe, steroid-refractory relapse:
  • "Clinically severe: EDSS increased from 2.0 to 8.0 (dependent in wheelchair)"
  • "Anatomically severe: Long-segment myelitis C5-T8"
  • "Functionally severe: Cannot walk, urinary retention"
  • Unresponsive to high-dose steroids (5 days completed, no improvement at day 7)"

2. Differential Diagnosis - RED FLAG:

• "Critical question: Is this MS or an MS mimic?
  • Longitudinally extensive transverse myelitis (C5-T8 = approximately 6-8 vertebral segments) is atypical for MS (MS myelitis usually less than 2 segments) [3,8]
  • Must exclude NMOSD (AQP4-IgG) and MOGAD (MOG-IgG) [7,8]
  • Also consider: Spinal cord compression (urgent neurosurgical review), infectious myelitis, spinal cord infarction"

3. Urgent Investigations:

• "Serology: AQP4-IgG, MOG-IgG (if positive, changes management dramatically) [7,8]
• MRI review: LETM ≥3 segments → NMOSD/MOGAD more likely; central cord involvement ('bright spotty lesions') → NMOSD [7]; conus involvement → MOGAD [8]
• Lumbar puncture: CSF analysis (cell count, protein, OCB, infectious workup)
• MRI brain: If brain lesions typical of MS (periventricular, juxtacortical) → supports MS; if area postrema/4th ventricle lesions → NMOSD [7]"

4. Management:

Assuming MS confirmed (AQP4/MOG negative, typical brain lesions):

• "Second-line treatment: Plasma exchange (PLEX) [7]

  • "Indications met: Severe relapse, no improvement 5-7 days post-steroids, functional catastrophe (EDSS 8.0)"
  • "Protocol: 5-7 exchanges over 10-14 days, 1.0-1.5 plasma volumes per exchange"
  • "Response rate: 40-60% experience moderate-marked improvement in steroid-refractory MS relapses [7]"
  • Timing: Initiate urgently—efficacy decreases if delayed > 3 months from relapse onset [7]"

• "Supportive care:

  • "Bladder: Intermittent self-catheterization (teach patient/family), monitor for UTIs"
  • "VTE prophylaxis: LMWH (high risk due to immobility)"
  • "Pressure area care: Regular turning, specialist mattress"
  • Neuro-rehabilitation: Intensive PT/OT once stabilized"

If NMOSD confirmed (AQP4-IgG positive):

• "Immediate plasma exchange (more effective in NMOSD than MS) [7]
• Long-term immunosuppression: Rituximab (first-line), tocilizumab, eculizumab, or sarilumab [7]
• Avoid MS DMTs (interferon-beta, fingolimod may worsen NMOSD) [7]"

5. Examiner Probes:

Q: "What if plasma exchange is not available at your hospital?"

• "Transfer to tertiary neurology center with apheresis capability. PLEX is a specialized procedure requiring:
  • Central venous access (tunneled catheter or large-bore peripheral)
  • Apheresis machine and trained operators
  • Critical care/neurology liaison for monitoring
  • If transfer not possible: Consider high-dose cyclophosphamide (600 mg/m² IV) as salvage therapy (limited evidence, expert centers only)"

Q: "The patient asks about prognosis—will he walk again?"

• "Honest discussion:
  • "With PLEX: 40-60% of steroid-refractory cases improve [7], but degree of improvement variable"
  • Complete recovery unlikely given severity (EDSS 8.0, extensive myelitis, steroid-refractory)
  • "Realistic goals: Improvement in strength allowing transfer with assistance, partial bladder function recovery"
  • Long-term: Incomplete recovery common in severe myelitis; focus on maximizing function through intensive rehabilitation, DMT to prevent future relapses (high-efficacy agent essential after this severe relapse)"

---

Scenario 3: Relapse vs. Pseudo-Relapse - Uhthoff Phenomenon

Viva Stem: "A 35-year-old woman with MS (stable on glatiramer acetate, no relapses for 3 years) calls the MS helpline in July saying her vision in the right eye has become blurry over the past 2 days after gardening in hot weather. She had optic neuritis in that eye 4 years ago which fully recovered. She is afebrile and feels otherwise well. What advice do you give?"

Model Answer:

1. Differential Diagnosis:

• "This could be:
  • "Uhthoff phenomenon (heat-induced pseudo-relapse): History of prior optic neuritis in same eye, symptom onset after heat exposure, transient [11]"
  • "True relapse (optic neuritis recurrence): Possible but less likely given temporal association with heat exposure"
  • Other causes: Uveitis, retinal pathology (less likely given history)"

2. Telephone Assessment:

• "Key questions to differentiate pseudo-relapse from true relapse:
  • "Duration: How long do symptoms last? If symptoms resolve after cooling down (within hours) → pseudo-relapse [11]. If persistent > 24 hours despite cooling → true relapse"
  • "Triggers: Heat exposure? (Uhthoff). Infection symptoms? (fever, urinary burning) → infection-related pseudo-relapse [11,18]"
  • "Pain: New periocular pain with eye movement suggests true relapse (new optic neuritis) [5]. Absence of pain suggests pseudo-relapse (old lesion reactivation)"
  • Severity: Is vision loss complete or just blurring? Severe vision loss more concerning for true relapse"

3. Immediate Management:

• "First-line approach:
  • "Cooling measures: Move to cool environment, cold drinks, cool shower, fan"
  • "Observe for 4-6 hours: If vision improves with cooling → Uhthoff phenomenon (pseudo-relapse), no treatment needed [11]"
  • If vision does not improve or worsens → Arrange urgent clinic review (same day/next day)"

4. Clinic Review (If Symptoms Persist):

• "Examination:

  • Visual acuity (Snellen chart), color vision (Ishihara plates), visual fields, RAPD (Marcus Gunn pupil), fundoscopy [5]
  • Temperature, urine dipstick (exclude infection)
  • Full neurological examination (any other new symptoms?)"

• "Investigations:

  • If examination shows new objective findings (reduced visual acuity, new RAPD, optic disc swelling) → True relapse, consider MRI orbits + brain
  • If examination normal or unchanged from baseline → Likely pseudo-relapse, reassure and educate on heat avoidance"

• "Treatment:

  • "If true relapse (new objective findings, symptoms persist > 24h, no improvement with cooling): High-dose methylprednisolone 1000mg × 3 days (oral acceptable) [2]"
  • If pseudo-relapse (Uhthoff): No steroids needed; educate on heat avoidance strategies (air conditioning, cooling vests, avoid hot baths/exercise in heat) [11]"

5. Examiner Probes:

Q: "What is the pathophysiology of Uhthoff phenomenon?"

• "Heat increases body temperature → demyelinated axons are exquisitely sensitive to temperature changes. Even 0.5°C increase can cause conduction block in demyelinated axons (sodium channel dysfunction) [11]. This unmasks pre-existing subclinical deficits from old lesions. Cooling restores conduction → symptoms resolve. No new inflammatory activity occurs, so steroids are not indicated."

Q: "The patient is distressed and insists on steroids 'to be safe.' How do you respond?"

• "I would empathize but explain:
  • "Steroids have risks: Insomnia, mood changes, GI upset, hyperglycemia, infection risk, long-term bone health if repeated courses"
  • "Steroids won't help pseudo-relapse: Uhthoff resolves with cooling alone; steroids target inflammation which isn't present in pseudo-relapse [11]"
  • "Overtreatment risks: Unnecessary steroid exposure when not indicated"
  • "Reassurance: Pseudo-relapse doesn't indicate disease worsening or need for DMT change; it's a transient, reversible phenomenon"
  • Safety net: If symptoms persist > 24 hours despite cooling or new symptoms develop → return immediately for reassessment"

---

Scenario 4: Pregnancy and Postpartum Relapse Risk

Viva Stem: "A 29-year-old woman with RRMS (currently on natalizumab) is planning pregnancy. She asks about relapse risk during pregnancy and postpartum, and whether she can continue her DMT. What counseling do you provide?"

Model Answer:

1. Relapse Risk During Pregnancy [14,20]:

• "Good news: Relapse risk decreases by 60-70% during pregnancy, especially in the third trimester [14,20]

• Mechanism: Pregnancy-induced immunotolerance (shift to Th2 cytokine profile, increased regulatory T-cells, hormonal immunomodulation)

• Evidence: Multiple studies show annualized relapse rate drops from ~0.7/year pre-pregnancy to ~0.2/year in trimester 3 [20]"

• "Postpartum risk (critical counseling point):

  • Relapse risk rebounds sharply in first 3 months postpartum [14,20]
  • Annualized relapse rate increases 2-3 fold (approximately 1.2-1.7 relapses/year in first 3 months postpartum) [14,20]
  • Risk highest in first 12 weeks postpartum, then gradually normalizes [20]"

2. DMT Management [14,20]:

Pre-Conception:

• "Natalizumab washout required:
  • Stop natalizumab 2-3 months before planned conception (long half-life, teratogenicity concerns, PML risk with rebound)
  • Risk of rebound disease activity after natalizumab cessation (can be severe)
  • "Options to mitigate rebound:"
    • Bridge with glatiramer acetate or interferon-beta (safer in pregnancy) until conception
    • Close monitoring (MRI at 3 months post-natalizumab cessation)
    • Some experts advocate continuing natalizumab until conception confirmed (individualized)"

During Pregnancy:

• "Most DMTs discontinued during pregnancy
• Possible exceptions (if high disease activity):
  • Glatiramer acetate (Category B, limited data but generally considered safe)
  • Interferon-beta (Category C, limited data, some use if high risk)
  • Decision individualized based on disease severity vs fetal risk"

Postpartum:

• "Critical to resume DMT promptly (within weeks postpartum if not breastfeeding) to prevent rebound relapses [14,20]
• Timing:
  • "If not breastfeeding: Resume natalizumab or switch to alternative high-efficacy DMT (ocrelizumab, alemtuzumab) within 2-4 weeks postpartum"
  • If breastfeeding: Discuss trade-offs (most DMTs contraindicated during breastfeeding; individual decision based on relapse risk vs breastfeeding benefits)"

3. Relapse Treatment During Pregnancy:

• "High-dose steroids generally safe after first trimester:
  • Methylprednisolone 1000 mg × 3-5 days can be used if moderate-severe relapse [14]
  • Avoid in first trimester if possible (theoretical risk of cleft palate, though data reassuring)
  • No teratogenicity concerns with short-course steroids in trimester 2-3"

4. Breastfeeding Considerations [20]:

• "Complex decision requiring individualized counseling:
  • "Benefits of breastfeeding: Nutritional, immunological, bonding"
  • "Risks of delaying DMT: High postpartum relapse risk (2-3× baseline) [14,20]"
  • Most DMTs contraindicated during breastfeeding (excreted in breast milk)
  • "Possible compromise: Exclusive breastfeeding for 3 months with close monitoring, then resume DMT (accepts higher relapse risk in early postpartum)"
  • Alternative: Formula feed and resume DMT immediately postpartum (minimizes relapse risk)"

5. Examiner Probes:

Q: "She has her baby and calls you 6 weeks postpartum with new leg weakness. How do you approach this?"

• "High index of suspicion for true relapse (postpartum is high-risk period [14,20])
• Exclude pseudo-relapse: Fatigue, sleep deprivation, stress (new mothers are exhausted—can unmask subclinical deficits)
• Exclude infection: UTI common postpartum, can cause pseudo-relapse [11,18]
• If true relapse:
  • High-dose steroids (safe if breastfeeding—minimal excretion in breast milk, though some advise pump-and-discard for 4 hours post-dose)
  • Urgent DMT resumption (if not already restarted)—this relapse indicates need for disease control
  • If breastfeeding: Discuss stopping breastfeeding to allow DMT resumption vs continuing with close monitoring"

Q: "What if she had 4 relapses per year before pregnancy—should management differ?"

• "Highly active disease changes risk-benefit calculation:
  • Higher risk of pregnancy relapses (even though overall risk decreases, absolute risk still significant with high baseline activity)
  • Catastrophic postpartum rebound risk (especially after stopping high-efficacy DMT like natalizumab)
  • "Management:"
    • Consider continuing natalizumab until conception confirmed or throughout pregnancy (after first trimester) in extreme cases (individualized, emerging practice)
    • Plan for immediate postpartum high-efficacy DMT resumption (within 2 weeks)
    • Monthly clinical monitoring during pregnancy
    • MRI surveillance (baseline, each trimester if high risk)
    • Counsel on realistic expectations: formula feeding may be necessary to allow DMT resumption"

---

Scenario 5: DMT Escalation Decision

Viva Stem: "A 33-year-old man with RRMS has been on interferon beta-1a (Rebif) for 18 months. Despite good adherence, he has experienced 3 relapses in the past 12 months (previous annualized relapse rate was 1.5/year pre-treatment). His latest MRI shows 8 new T2 lesions and 3 gadolinium-enhancing lesions compared to baseline. Current EDSS is 3.5 (increased from 2.0 at diagnosis). He asks whether his current treatment is working. What is your assessment and recommendation?"

Model Answer:

1. Assessment of Treatment Response [6,10,15]:

• "This patient has evidence of treatment failure based on multiple criteria:
  • "Clinical: 3 relapses in 12 months (≥1 relapse/year on DMT indicates suboptimal control [6,10])"
  • "Radiological: 8 new T2 lesions + 3 gadolinium-enhancing lesions (MRI activity indicating ongoing inflammation despite DMT)"
  • "Disability progression: EDSS increased from 2.0 → 3.5 in 18 months (≥1.0 point increase suggests progression [16])"
• Paradox: Interferon-beta reduces relapses by ~30-35% [4,10], so ARR should have decreased from 1.5 → ~1.0/year. Instead, ARR is 3.0/year (worse than pre-treatment)—likely natural disease course but highlights treatment inadequacy."

2. Definition of Treatment Failure [6,10]:

• "NEDA (No Evidence of Disease Activity) is the treatment goal [6]:
  • No relapses
  • No MRI activity (no new T2 lesions, no gadolinium-enhancing lesions)
  • No disability progression (EDSS stable)
• This patient fails all 3 NEDA criteria → Clear indication for DMT escalation"

3. Escalation Strategy [6,10]:

Step 1: Explain Treatment Failure

• "Interferon-beta is a first-line moderate-efficacy DMT. Unfortunately, your disease is more active than this medication can control. This is not your fault—it's the nature of your MS being more aggressive than anticipated. We need to escalate to a stronger medication to prevent further relapses and disability."

Step 2: Options for Escalation (Moderate → High-Efficacy DMTs)

Step 3: Individualized Recommendation

• "For you, I would recommend ocrelizumab or natalizumab as first-line escalation:
  • "Ocrelizumab: Convenient (every 6 months infusion), excellent efficacy, good safety profile if immunoglobulin levels monitored"
  • "Natalizumab: Most convenient (monthly infusion, can fit around work), highly effective, but requires JC virus monitoring (if JC positive, PML risk ~1:1000 after 2 years, increasing with duration)"
  • "Alemtuzumab: Very effective but requires intensive monitoring (monthly blood/urine for 4 years)—usually reserved if other high-efficacy agents fail or contraindicated"
  • Decision: Shared decision-making based on your priorities (convenience, risk tolerance, family planning)"

4. Timing and Logistics:

• "Start new DMT as soon as possible (within 4-8 weeks):
  • "Interferon-beta washout: 4 weeks (short half-life)"
  • "Baseline investigations: MRI brain/spine, FBC, LFTs, serology (HIV, hepatitis B/C, VZV), JC virus antibody (if considering natalizumab)"
  • Vaccination (if ocrelizumab): Update vaccinations before starting (flu, pneumococcal, meningococcal, COVID-19)—live vaccines contraindicated once on B-cell depleting therapy"

5. Expected Outcomes:

• "Realistic expectations with high-efficacy DMT:
  • 65-70% reduction in relapse rate [4,10,19] → ARR should decrease to ~0.5-1.0/year
  • 80-90% reduction in MRI activity → minimal new lesions
  • "Goal: NEDA (no relapses, no MRI activity, no progression)"
  • Some patients achieve complete disease remission on high-efficacy DMT (no disease activity for years)"

6. Examiner Probes:

Q: "What if the patient is JC virus positive and you want to use natalizumab—how do you counsel him?"

• "JC virus positivity increases PML risk with natalizumab:
  • "Risk stratification:"
    • JC negative: PML risk less than 1:10,000 (very low) [19]
    • JC positive, less than 2 years treatment, no prior immunosuppression: ~1:1000 [19]
    • JC positive, > 2 years treatment: ~3-5:1000 (increases with duration) [19]
    • JC positive + prior immunosuppression: ~10:1000 [19]
  • "Risk mitigation:"
    • MRI brain every 3-6 months (detect asymptomatic PML early)
    • JC virus antibody index every 6 months (rising index = higher risk)
    • Patient education on PML symptoms (cognitive decline, personality change, focal weakness—urgent MRI if suspected)
    • Extended interval dosing (every 6-8 weeks instead of 4 weeks) may reduce PML risk (emerging practice, off-label)
  • Alternatives: If patient uncomfortable with PML risk → ocrelizumab or alemtuzumab"

Q: "He starts ocrelizumab and has no relapses for 2 years, but MRI shows 2 new T2 lesions. What do you do?"

• "Subclinical MRI activity despite clinical stability:
  • This represents MRI disease activity despite no clinical relapses (partial treatment response)
  • "Options:"
    1. Continue ocrelizumab: Some new lesions can occur even on high-efficacy DMT; if no clinical impact and trend improving, may accept
    2. Optimize ocrelizumab dosing: Check B-cell depletion (CD19 count)—if B-cells not fully depleted, may indicate suboptimal dosing or antibody development
    3. Switch to alternative high-efficacy DMT: Alemtuzumab or cladribine (different mechanism)
  • My approach: Treat the MRI lesions as 'silent relapses'—likely switch DMT, especially if ≥3 new lesions or patient young with high functional demands"

---

11. Patient/Layperson Explanation

What is an MS Relapse?

An MS relapse (also called an exacerbation, flare, or attack) is a sudden worsening of your multiple sclerosis symptoms, or the appearance of new symptoms, caused by new inflammation in your brain or spinal cord. Think of your nerves like electrical wires—normally they're insulated with a protective coating called myelin. In MS, your immune system mistakenly attacks this myelin coating, damaging it. When this happens suddenly during a relapse, the electrical signals traveling along your nerves get disrupted, causing symptoms like weakness, numbness, vision problems, or balance difficulties.

In simple terms: Your MS symptoms flare up suddenly, usually lasting at least 24 hours (not just brief minutes or hours). Most relapses improve with treatment, but some symptoms may persist.

What Causes a Relapse?

Relapses happen when your immune system becomes more active and attacks the myelin in your brain or spinal cord. Sometimes there's a trigger:

• Infections (especially urinary or chest infections) can trigger a relapse or make existing symptoms temporarily worse (called a "pseudo-relapse")
• Stress (physical or emotional) may increase relapse risk
• Postpartum period (first 3 months after giving birth) carries higher relapse risk
• Stopping your disease-modifying therapy (DMT) increases relapse risk

However, many relapses happen spontaneously without an obvious trigger—this is just the nature of MS.

How Do You Know It's a Real Relapse?

A true relapse must meet these criteria:

1. New or worsening symptoms lasting at least 24 hours (not brief minutes or hours)
2. No fever or infection (infections can cause "pseudo-relapses" where old symptoms temporarily worsen)
3. At least 30 days since your last relapse started

Pseudo-relapses are common—they're when old symptoms temporarily worsen due to:

• Infection (especially urine infections)—treating the infection resolves symptoms
• Heat exposure (hot weather, hot baths, fever)—symptoms improve with cooling
• Fatigue or stress—symptoms worse at end of day but improve with rest

Important: If you have a urine infection or fever, your doctor will treat that first and see if your symptoms improve within 48 hours before diagnosing a true relapse.

How is an MS Relapse Treated?

1. Exclude Infection First (Very Important)

• Why: Infections make MS symptoms worse temporarily (pseudo-relapse) without actually being a new relapse
• What happens: Your doctor will check your urine, temperature, and look for signs of infection
• If infection found: Treat the infection first (antibiotics for UTI, etc.); reassess in 48 hours
• If symptoms resolve: It was a pseudo-relapse, not a true relapse—no steroids needed

2. High-Dose Steroids (If True Relapse and Moderate-Severe Impact)

• What: Methylprednisolone 1000 mg daily for 3-5 days
• How: Tablets (oral) or intravenous (IV drip)—research shows tablets work just as well as IV for most relapses [2]
• How they work: Steroids reduce the inflammation in your brain/spinal cord, helping your symptoms recover faster
• Timeline: You'll usually start feeling better within 3-7 days; maximal recovery takes 4-12 weeks
• Important: Steroids speed up recovery by 1-2 weeks, but they don't change your long-term disability or prevent future relapses—that's what your disease-modifying therapy (DMT) does

Side effects to expect (usually mild and short-lived):

• Difficulty sleeping (take steroids in the morning)
• Increased appetite, metallic taste
• Mood changes (feeling "wired" or emotional)
• Indigestion (your doctor will give you a stomach-protecting tablet)
• Higher blood sugars (important if you're diabetic)

3. If Steroids Don't Work (Rare):

• What: Plasma exchange (PLEX)—a procedure that filters your blood to remove harmful antibodies
• When: Reserved for severe relapses that don't improve after steroids (about 5-10% of cases)
• How it works: 5-7 treatments over 2 weeks; 40-60% of people improve [7]

4. Symptom Management:

• Pain: Painkillers (paracetamol, ibuprofen) or nerve pain medications (gabapentin, pregabalin)
• Spasticity/stiffness: Muscle relaxants (baclofen, tizanidine)
• Bladder problems: Medications to help bladder control; bladder training
• Fatigue: Rest, pacing yourself, sometimes medication (amantadine)
• Rehabilitation: Physiotherapy, occupational therapy to maximize your recovery

5. Prevent Future Relapses:

• Disease-modifying therapies (DMTs): These are medications you take regularly (daily, weekly, or monthly depending on type) to reduce relapse frequency by 30-70%
• If you have frequent relapses (≥1 per year despite DMT): Your doctor may switch you to a stronger DMT
• Lifestyle: Treat infections promptly, avoid overheating, manage stress, stop smoking, consider vitamin D supplements

What to Expect: Recovery from a Relapse

Most people (70-80%) improve significantly within 4-12 weeks

• First few days: Symptoms may initially worsen or stay stable
• Week 1-2: Gradual improvement begins (faster if you received steroids)
• Weeks 4-12: Continued recovery; most improvement happens in this timeframe
• Beyond 3 months: Further recovery possible but slower

Complete recovery vs incomplete recovery:

• 40-50% of people recover completely with no lasting symptoms [11]
• 20-30% have some residual (leftover) symptoms that don't fully go away [11]
• Factors affecting recovery: Age (younger = better recovery), type of relapse (optic neuritis and sensory relapses recover better than motor/cerebellar relapses), how quickly you got treatment

Each relapse is different—you may recover completely from one relapse but have residual symptoms from another.

When to Seek Help

Contact your MS nurse or neurologist if:

• You have new symptoms lasting more than 24 hours
• Old symptoms are much worse than usual for more than 24 hours
• You're unsure if it's a relapse or a pseudo-relapse
• You think you might have an infection (fever, burning when urinating, cough with colored phlegm)

Call 999 (or your emergency number) immediately if:

• You have severe weakness (can't move your arms or legs)
• You have difficulty breathing
• You have complete loss of vision in one or both eyes
• You're confused or drowsy
• You have chest pain or severe headache

Remember: Not every symptom change is a relapse. Many are pseudo-relapses (infection, heat, fatigue) that don't need steroid treatment. Always check for infection first, especially urine infections—treating the infection often resolves the symptoms within 48 hours.

Living Well with MS: Reducing Relapse Risk

Things you can control:

1. Take your DMT as prescribed—this is the single most important factor for preventing relapses [4,10,15]
2. Treat infections promptly—don't delay seeing your doctor if you suspect a UTI or chest infection [11,18]
3. Avoid overheating—stay cool in hot weather, avoid hot baths, cool down if feverish [11]
4. Stop smoking—smoking increases relapse risk and speeds up disability progression
5. Manage stress—easier said than done, but chronic stress may increase relapse risk
6. Vitamin D—many neurologists recommend 2000-4000 IU daily (discuss with your doctor)
7. If planning pregnancy—discuss with your neurologist before stopping DMT; plan for postpartum DMT resumption to prevent rebound relapses [14,20]

The Bottom Line: MS relapses are unpredictable, but modern treatments (steroids for acute relapses, DMTs for prevention) significantly reduce their frequency and impact. Most relapses improve within weeks to months, especially with early treatment. The key is knowing when to seek help, excluding infections before assuming it's a true relapse, and staying on your DMT to prevent future attacks.

---

12. References

Primary Guidelines & Diagnostic Criteria

1. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol. 2001;50(1):121-127. PMID: 11456302. DOI: 10.1002/ana.1032

2. Le Page E, Veillard D, Laplaud DA, et al. Oral versus intravenous high-dose methylprednisolone for treatment of relapses in patients with multiple sclerosis (COPOUSEP): a randomised, controlled, double-blind, non-inferiority trial. Lancet. 2015;386(9997):974-981. PMID: 26135706. DOI: 10.1016/S0140-6736(15)61137-0

3. McGinley MP, Goldschmidt CH, Rae-Grant AD. Diagnosis and Treatment of Multiple Sclerosis: A Review. JAMA. 2021;325(8):765-779. PMID: 33620411. DOI: 10.1001/jama.2020.26858

Systematic Reviews & Meta-Analyses

4. Gonzalez-Lorenzo M, Ridley B, Minozzi S, et al. Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis. Cochrane Database Syst Rev. 2024;1:CD011381. PMID: 38174776. DOI: 10.1002/14651858.CD011381.pub3

5. Bennett JL, Costello F, Chen JJ, et al. Optic neuritis and autoimmune optic neuropathies: advances in diagnosis and treatment. Lancet Neurol. 2023;22(1):89-100. PMID: 36155661. DOI: 10.1016/S1474-4422(22)00187-9

MS Overview & Pathophysiology

6. Yamout BI, Alroughani R. Multiple Sclerosis. Semin Neurol. 2018;38(2):212-225. PMID: 29791948. DOI: 10.1055/s-0038-1649502

7. Huda S, Whittam D, Bhojak M, et al. Neuromyelitis optica spectrum disorders. Clin Med (Lond). 2019;19(2):169-176. PMID: 30872305. DOI: 10.7861/clinmedicine.19-2-169

8. Banwell B, Bennett JL, Marignier R, et al. Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria. Lancet Neurol. 2023;22(3):268-282. PMID: 36706773. DOI: 10.1016/S1474-4422(22)00431-8

9. Bigi S, Banwell B. Pediatric multiple sclerosis. J Child Neurol. 2012;27(11):1378-1383. PMID: 22914372. DOI: 10.1177/0883073812452784

Disease-Modifying Therapies

10. Rae-Grant A, Day GS, Marrie RA, et al. Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis. Neurology. 2018;90(17):777-788. PMID: 29686116. DOI: 10.1212/WNL.0000000000005347

11. Kalincik T. Multiple Sclerosis Relapses: Epidemiology, Outcomes and Management. A Systematic Review. Neuroepidemiology. 2015;44(4):199-214. PMID: 25997994. DOI: 10.1159/000382130

12. Auger JP, Zimmermann M, Faas M, et al. Metabolic rewiring promotes anti-inflammatory effects of glucocorticoids. Nature. 2024;628(8009):835-843. PMID: 38600378. DOI: 10.1038/s41586-024-07282-7

Pregnancy & Postpartum

14. Gavoille A, Rollot F, Casey R, et al. Therapeutic Management During Pregnancy and Relapse Risk in Women With Multiple Sclerosis. JAMA Neurol. 2025 Jan 6. Online ahead of print. PMID: 40758347. DOI: 10.1001/jamaneurol.2025.2550

15. Hennessy B, Zierhut ML, Kracker H, et al. Comparative Efficacy of Relapsing Multiple Sclerosis Therapies: Model-Based Meta-Analysis. Mult Scler Relat Disord. 2022;65:103908. PMID: 35803162. DOI: 10.1016/j.msard.2022.103908

Disability & Outcomes

16. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33(11):1444-1452. PMID: 6685237. DOI: 10.1212/wnl.33.11.1444

17. Lublin FD, Häring DA, Ganjgahi H, et al. How patients with multiple sclerosis acquire disability. Brain. 2022;145(9):3147-3161. PMID: 35104840. DOI: 10.1093/brain/awac016

Infection & Triggers

18. Finsterer J. SARS-CoV-2 triggered relapse of multiple sclerosis. Clin Neurol Neurosurg. 2022;217:107210. PMID: 35305393. DOI: 10.1016/j.clineuro.2022.107210

19. Margoni M, Preziosa P, Filippi M, et al. Anti-CD20 therapies for multiple sclerosis: current status and future perspectives. J Neurol. 2022;269(3):1316-1334. PMID: 34382120. DOI: 10.1007/s00415-021-10744-x

20. Schubert C, Steinberg L, Peper J, et al. Postpartum relapse risk in multiple sclerosis: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2023;94(6):718-725. PMID: 36807056. DOI: 10.1136/jnnp-2022-330533

Secondary Progressive MS

21. Cree BAC, Arnold DL, Chataway J, et al. Secondary Progressive Multiple Sclerosis: New Insights. Neurology. 2021;97(8):378-388. PMID: 34088878. DOI: 10.1212/WNL.0000000000012323

22. Ziemssen T, Bhan V, Chataway J, et al. Secondary Progressive Multiple Sclerosis: A Review of Clinical Characteristics, Definition, and Treatment Options. Neurol Neuroimmunol Neuroinflamm. 2023;10(1):e200064. PMID: 36414428. DOI: 10.1212/NXI.0000000000200064

---

Last Reviewed: 2026-01-10 | MedVellum Editorial Team

---

Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. Clinical decisions should account for individual patient circumstances. Always consult appropriate specialists and refer to the most current evidence-based guidelines. This information is not a substitute for professional medical advice, diagnosis, or treatment.